- Home
- TEL vs ALNY Comparison
TEL vs ALNY Comparison
Compare TEL & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEL
- ALNY
- Stock Information
- Founded
- TEL 1941
- ALNY 2002
- Country
- TEL Ireland
- ALNY United States
- Employees
- TEL N/A
- ALNY N/A
- Industry
- TEL Industrial Machinery/Components
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- TEL Technology
- ALNY Health Care
- Exchange
- TEL Nasdaq
- ALNY Nasdaq
- Market Cap
- TEL 49.8B
- ALNY 40.4B
- IPO Year
- TEL 2007
- ALNY 2004
- Fundamental
- Price
- TEL $177.66
- ALNY $315.10
- Analyst Decision
- TEL Buy
- ALNY Strong Buy
- Analyst Count
- TEL 10
- ALNY 24
- Target Price
- TEL $166.40
- ALNY $345.70
- AVG Volume (30 Days)
- TEL 1.6M
- ALNY 881.3K
- Earning Date
- TEL 07-23-2025
- ALNY 07-31-2025
- Dividend Yield
- TEL 1.60%
- ALNY N/A
- EPS Growth
- TEL N/A
- ALNY N/A
- EPS
- TEL 4.58
- ALNY N/A
- Revenue
- TEL $16,026,000,000.00
- ALNY $2,348,099,000.00
- Revenue This Year
- TEL $6.24
- ALNY $32.73
- Revenue Next Year
- TEL $7.32
- ALNY $31.50
- P/E Ratio
- TEL $38.68
- ALNY N/A
- Revenue Growth
- TEL 1.23
- ALNY 17.21
- 52 Week Low
- TEL $116.30
- ALNY $205.87
- 52 Week High
- TEL $178.03
- ALNY $333.70
- Technical
- Relative Strength Index (RSI)
- TEL 72.18
- ALNY 53.21
- Support Level
- TEL $170.58
- ALNY $313.74
- Resistance Level
- TEL $175.03
- ALNY $324.82
- Average True Range (ATR)
- TEL 2.82
- ALNY 9.20
- MACD
- TEL 0.41
- ALNY -1.83
- Stochastic Oscillator
- TEL 99.29
- ALNY 32.49
About TEL TE Connectivity Ltd. New Switzerland Registered Shares
TE Connectivity is the largest electrical connector supplier in the world, supplying interconnect and sensor solutions to the transportation, industrial, and communications markets. With operations in 150 countries and over 500,000 stock-keeping units, TE has a broad portfolio that forms the electrical architecture of its end customers' cutting-edge innovations.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.